About Us Contact Us Disclaimer Sitemap
  New Old
left «« +1 «« -1 right
  Equity Analysis
Gainers & Losers
Out & Under Performers
Only Buyers & Sellers
Advances & Declines
New Highs & Lows
5 Day's Up & Down
Historical Returns
  News Analysis
Corporate Action
  Corporate Info
  Other Market
Company Profile  
Dr. Reddys Laboratories Ltd.
BSE Code 500124
ISIN Demat INE089A01023
Book Value(Rs.) 725.85
Dividend Yield % 0.74
Market Cap(Rs. in millions) 446580.33
P/E 38.88
EPS 69.18
Face Value(Rs.) 5  

Dr Reddy's Laboratories is a 25-year old company catering  to the needs of the pharmaceutical sector. Dr Reddy's started its operation in 1984 in the Actove Pharmaceutical Ingredients (API) segment, with a single drug in 60 tonne facility near Hyderabad. In 1986 its shipped its first consignment of Methyldopa drug to West Germany.

It is among the top three API players in world. Dr Reddy's, a global pharmaceutical company, has its headquarters located in India. It has a global presence in more than 100 countries, with subsidiaries in the US, UK, Russia, Germany and Brazil; joint ventures in China, South Africa and Australia; representative offices in 16 countries and third-party distribution set ups in 21 countries.

It is first pharmaceutical company in Asia, outside Japan, to be listed on the NYSE. It is largest player in the custom pharmaceutical services (CPS) business in India.The pharma major has launched brands like Ciprolet, Nise, Enam, Stamlo, Omez, and Ketorol among others.

Dr Reddy’s Laboratories launched Imitrex (sumatriptan succinate) tablets in dosages of 25mg, 50mg, and 100mg in the US. It is the authorized generic version of GlaxoSmithKline’s Imitrex. It is first company to launch Imitrex  (generic version) in the US market. These tablets are for treatment of acute treatment of migraine in adults.

The company is having

  • 6 FDA-inspected plants in INDIA
  • 1 Cytotoxic facility
  • 1 FDA-inspected plant in Mexico
  • 1 FDA-inspected plant in Mirfield, UK
  • 3 Technology development centers
  • (2 in Hyderabad, INDIA; 1 in Cambridge, UK)


In June 2009, Dr. Reddy's announces strategic alliance with GSK to develop and market selected products across emerging markets outside India.

In October 2010, Dr Reddy's Laboratories and SoluBest, an Israel-based clinical-stage developer, closed a collaboration agreement to develop a new, proprietary formulation of one of latter’s pipeline compounds.

In October 2010, Dr Reddy’s Laboratories has inked a licensing pact with Cipla for exclusive marketing rights of a portfolio of OTC and prescription products in the Russian and Ukraine markets.

In November 2010, GlaxoSmithKline and Dr. Reddy's agreed to the sale of US Penicillin Facility and Products where GSK will transfer ownership of its penicillin manufacturing sites in Bristol, United States and rights for the Augmentin and Amoxil brands in the US to Dr.Reddy’s Laboratories.

In December 2010, Dr. Reddy's enters into an agreement with R-Pharma of Russia in the areas of high-technology and knowledge sharing.

In January 2011, Dr Reddy's Laboratories (DRL) has entered into a pact with UK-based contract research firm Argenta for collaboration in drug discovery. As per this pact, the duo will be working in the area of pain and inflammation.

In March 2011, Dr. Reddy’s Laboratories completed the acquisition of GlaxoSmithKline’s (GSK) United States oral penicillin facility and product portfolio pursuant to the agreement signed and announced by the companies on November, 2010.

In September 2011, Dr. Reddy's Laboratories has entered into a settlement agreement with Pfizer which will resolve litigation related to Lipitor(R) Tablets, known generically as Atorvastatin Calcium tablets.

In 2011-Dr Reddy's launches Levocetirizine tablets in US-Dr Reddy's launches generic allergy drug in US-Dr. Reddy's launches pegfilgrastim in India under the brand name 'Peg-grafeelIn 2012 -Dr. Reddy's launches Quetiapine Fumarate Tablets.

In 2015- Dr. Reddy's Laboratories bought the established brands of Belgian drugmaker UCB SA in South Asia for 8 billion rupees ($128.38 million). Dr. Reddy's Laboratories also signed a licensing pact with XenoPort for their experimental treatment to treat plaque psoriasis.                                                               

In 2016 Dr. Reddy’s launched ‘Purple Health’ in India, a patient centric platform to deliver solutions that address unmet needs of patients.

2017- Dr. Reddy's Laboratories announces the launch of Clofarabine Injection in the U.S. Market
Dr. Reddy's Laboratories announces the launch of generic Azacitidine for Injection in the Canadian Market


Pharma Services and API business

Under this it offer over 100 molecules to customers across the world. APIs are its core strength, having a wide range of portfolio. It submits the largest number of US DMF from India. It entered into the custom pharmaceutical services (CPS) in 2001 .With acquisition of Roche’s API manufacturing unit Mexico in 2005, it got boost in the CPS business. It also acquired the small molecule business of Dow Pharma at its Mirfield and Cambridge sites, UK in 2008 , strengthening its CPS business.

Generics Medicines

It also manufactures generic medicines with business spread across India, Russia, US and Germany. It is amongst the top ten players in India.

Proprietary Products

Under this it includes NCE research, biologics business and differentiated formulations conducted in the US. Under this it has launched Grafeel(Filgrastim) and Reditux(Rituximab).


  • It was ranked among top ten in ‘The Best Companies to Work for in India’ Survey conducted jointly by Business Today, Mercer Human Resource Consulting and TNS India.
  • It received the Recruitment and Staffing Best in Class (RASBIC) Award for the ‘Best Use of Technology for Recruiting’ at the Asia Pacific HRM Congress.
  • It received the Certificate of Merit for Innovative Training Practices among Indian organization by ISTD (Indian Society for Training and Development).
  • NHRD Inspire award 2011 for Learning & Development for organization best practices in the area of competency framework in the Non-IT sector


Terms & Conditions Copyright ©ATLAS All rights reserved. Designed || Developed & Content Powered By Accord Fintech Pvt.Ltd.

Important Links : SEBI | NSE | BSE | RBI | CDSL | NSDL | Investor Grievance| Policy
SEBI REG. NO. NSE : CASH INB230956935; FO INF230956935; CURRENCY INE230956935 | BSE : CASH INB010956937; FO INF010956937
PMS : INP000000530 | AMFI : ARN0770 | CDSL : IN-DP-CDSL-465-2008